艾可菲美股招股说明书(2026-07-24版)

Equifax Inc. $500,000,000 5.000% Senior Notes Due 2029$500,000,000 5.650% Senior Notes Due 2033 We are offering $500,000,000 aggregate principal amount of 5.000% senior notes due August15, 2029 (the “2029 notes”) and $500,000,000aggregate principal amount of 5.650% senior notes due August15, 2033 (the “2033 notes” and, together with the 2029 notes, the “notes”). The 2029notes will mature on August15, 2029 and the 2033 notes will mature on August15, 2033. The notes will be issued only in minimum denominationsof $2,000 and integral multiples of $1,000 in excess thereof. We will pay interest on the notes semi-annually in arrears on February15 andAugust15 of each year, beginning on February15, 2027. We may redeem some or all of the notes of each series at our option, in whole or in part, at any time and from time to time at the applicableredemption prices set forth in this prospectus supplement under “Description of Notes—Optional Redemption.” If we experience a change ofcontrol triggering event and we have not otherwise elected to redeem the notes, we will be required to offer to repurchase the notes from holders asdescribed under “Description of Notes—Change of Control Offer.” The notes will be our senior unsecured obligations and will rank equally with our other existing and future unsecured senior debt from time to timeoutstanding. The notes are a new issue of securities with no established trading market. The notes will not be listed on any securities exchange or quoted on anyautomated dealer quotation system. Investing in the notes involves risks. You should consider carefully the risks set forth in “Risk Factors” beginningon page S-5, as well as the risks set forth in our other filings with the Securities and Exchange Commission (the“SEC”), which are incorporated by reference in this prospectus supplement and the accompanying prospectus,before investing in the notes. Neither the SEC nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy oraccuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. The underwriters expect to deliver the notes in book-entry form only through the facilities of The Depository Trust Company (“DTC”) for theaccounts of its participants, including Clearstream Banking, S.A. (“Clearstream”), and Euroclear Bank SA/NV (“Euroclear”), on or about July29,2026 (the “Issue Date”). WellsFargoSecuritiesCitizensCapitalMarketsUSBancorp Table of Contents TABLE OF CONTENTSProspectus Supplement About This Prospectus SupplementWhere You Can Find More InformationInformation We Incorporate by ReferenceForward-Looking StatementsSummaryRisk FactorsUse of ProceedsCapitalizationDescription of NotesCertain United States Federal Income Tax ConsequencesUnderwritingLegal MattersExperts Prospectus About This ProspectusWhere You Can Find More InformationIncorporation of Certain Information by ReferenceUse of ProceedsLegal MattersExperts Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and the notes offeredhereby. The second part, the accompanying prospectus, gives more general information, some of which may not apply to this offering. Generally, when we refer to this “prospectus,” we are referring to both documents combined. You should read both this prospectus supplement and theaccompanying prospectus, together with additional information described below under the headings “Where You Can Find More Information” and“Information We Incorporate by Reference.” If there is any inconsistency between the information in this prospectus supplement and the accompanyingprospectus, you should rely on the information in this prospectus supplement. You should rely only on the information contained in or incorporated by reference into this prospectus supplement, the accompanying prospectus or anyfree writing prospectus with respect to this offering filed by us with the SEC. We have not, and the underwriters have not, authorized anyone to provideyou with different or additional information. If anyone provides you with different or inconsistent information, you should not rely on it. You shouldassume that the information appearing in this prospectus supplement, the accompanying prospectus, any free writing prospectus with respect to theoffering filed by us with the SEC and the documents incorporated by reference herein and therein is accurate only as of their respective dates. Ourbusiness, financial condition, results of operations and prospects may have changed since those dates. We are not, and the underwriters are not, making an offer to sell or soliciting an offer to buy securities in any jurisdiction in which an offer, solicitationor sale is not permitted or in which the person making such offer or solicitation is not qualified to do so or to whom